In conclusion, targeting STING is a viable therapeutic approach for viral pneumonia, and inhibiting STING also reduces GSDMD activation, thereby decreasing NETs formation and slowing the progression of viral pneumonia. Here, GSDMD is linked to viral pneumonia.